athenahealth vs Becton Dickinson
Side-by-side comparison of AI visibility scores, market position, and capabilities
$1.7B annual revenue; 160K+ providers, 117M patients; 18.15% EHR market share; 6,713+ companies using 2025; acquired by Bain Capital & Hellman & Friedman Nov 2021 at $17B; AI interoperability 2025
About
athenahealth is a cloud-based electronic health records (EHR), medical billing, and practice management company founded in 1997 and headquartered in Watertown, Massachusetts. The company was built on the principle that healthcare administration should be managed as a service — with athenahealth absorbing the complexity of payer rule updates, regulatory compliance, and billing workflows so that physicians and clinical staff can focus entirely on patient care. Its cloud-native architecture, deployed before most EHR competitors moved to the cloud, remains a core technical differentiator.\n\nathenahealth's platform — athenaOne — integrates EHR, revenue cycle management, patient engagement, and care coordination in a single system used by over 160,000 providers across 117 million patient records. The company serves ambulatory practices ranging from solo physicians to large health systems and medical groups. Its continuously updated rules engine processes millions of payer transactions daily, enabling higher clean claim rates and faster reimbursement compared to on-premise EHR alternatives. athenahealth holds an 18.15% share of the US ambulatory EHR market.\n\nathenahealth is currently owned by a private equity consortium of Bain Capital and Hellman & Friedman, which acquired the company in 2019 for $5.7 billion. Annual revenue stands at approximately $1.7 billion. The company competes with Epic, eClinicalWorks, and Oracle Health in the ambulatory EHR market. Its managed-service model, shared payer network data, and cloud-native infrastructure continue to make it a compelling choice for ambulatory providers who prioritize revenue cycle performance and reduced administrative burden.
Franklin Lakes NJ medical technology (NYSE: BDX) at $21.8B FY2025 revenue (+8.2%); $17.5B Reverse Morris Trust spinoff with Waters (2025), Edwards critical care acquisition $4.2B (2024) competing with Baxter for infusion systems.
About
Becton, Dickinson and Company (BD) is a Franklin Lakes, New Jersey-based global medical technology company — publicly traded on the New York Stock Exchange (NYSE: BDX) as an S&P 500 Health Care component — manufacturing and selling medical supplies, devices, laboratory equipment, and diagnostic products through approximately 74,000 employees serving healthcare institutions, clinical laboratories, pharmaceutical companies, and life science researchers in over 190 countries. In fiscal year 2025 (ended September 30, 2025), BD reported full-year revenue of $21.8 billion (up 8.2% year-over-year) with Q4 FY2025 revenue of $5.9 billion (+8.3% reported, +3.9% organic growth), and declared a quarterly dividend of $1.05 per share (+1%). Founded in 1897 in New York City by Maxwell Becton and Fairleigh Dickinson Sr. as a thermometer and surgical instrument maker, BD has grown through 125+ years of acquisitions to become a Fortune 500 ($21.8B revenue, #211 on 2024 Fortune 500) global medtech leader. The company operates through three segments: BD Medical (~50% of revenue, IV catheters, syringes, prefillable drug delivery systems, and medication management solutions), BD Life Sciences (flow cytometry, microbiology, molecular diagnostics, and lab automation), and BD Interventional (advanced patient monitoring, interventional cardiology, and peripheral vascular interventions). BD invests $1.2+ billion annually in R&D. In 2024, BD acquired Edwards Lifesciences' critical care monitoring unit for $4.2 billion.
AI Visibility Head-to-Head
Key Details
Capabilities & Ecosystem
Capabilities
Integrations
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.